Where Metsera’s data fit in the obesity landscape

New Phase IIb data from Metsera’s GLP-1R agonist MET-097i raise the possibility of a best-in-class profile across efficacy, safety and dosing interval, underscoring why Pfizer agreed to pay heavily to acquire the biotech.

On Monday, Metsera Inc. (NASDAQ:MTSR) announced initial results from the 239-patient Phase IIb VESPER-1 study, showing once-weekly MET-097i, at the highest dose of 1.2 mg, led to placebo-adjusted weight loss of 14.1% after 28 weeks of treatment. An exploratory analysis at 36 weeks showed continued weight loss, indicating its efficacy had not yet plateaued...